Fistula, unspecified joint
Methodology & AI Transparency ⓘ
Fistula, unspecified joint Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Recognized across U.S.
- 2 Real-world patient consensus: Diagnostic registry M25.10: Fistula, unspecified joint is managed within Arthritis & Joints.
- 3 Typical cash cost range: Primary evaluation for Fistula, unspecified joint incorporates weight-bearing joint radiography [Fistula, unspecified joint M25.10] and symptom diary review.
- 4 Top reported side effects / signs: Key Arthritis & Joints biomarkers for Fistula, unspecified joint (M25.10): hs-CRP & Erythrocyte in Fistula, unspecified joint (M25.10: Sedimentation Rate) & Weight-Bearing Joint Radiograph [Fistula, unspecified joint M25.10] (Preserved joint-space width (M25.10)).
Ask our AI Specialists anything about Fistula, unspecified joint
What Is Fistula, unspecified joint?
Recognized across U.S. clinical coding as M25.10 (Arthritis & Joints), Fistula, unspecified joint is evaluated via weight-bearing joint radiography [Fistula, unspecified joint M25.10] to align day-to-day symptom relief with long-term physiological stability.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Fistula, unspecified joint (M25.10, Arthritis & Joints) reflects monosodium urate or in Fistula, unspecified joint (M25.10: calcium pyrophosphate crystal). longitudinal control is benchmarked via hs-CRP & Erythrocyte in Fistula, unspecified joint (M25.10: Sedimentation Rate).
Common Symptoms & Clinical Signs
- • Presentation of Fistula, unspecified joint (M25.10): brief morning joint in Fistula, unspecified joint (M25.10: stiffness)
- • Secondary Fistula, unspecified joint clinical sign: sudden, intensely painful, in Fistula, unspecified joint (M25.10: red swollen big-toe)
- • Symptom flares in Fistula, unspecified joint correlating with hs-CRP & Erythrocyte in Fistula, unspecified joint (M25.10: Sedimentation Rate) deviation outside hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M25.10)
- • Functional arthritis & joints impact requiring weight-bearing joint radiography [Fistula, unspecified joint M25.10] evaluation (M25.10)
Fistula, unspecified joint Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M25.10 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Osteoarthritis, Gout & Joint Pain | NLM Clinical Tables |
| Diagnostic / Lab Marker: hs-CRP & Erythrocyte in Fistula, unspecified joint (M25.10: Sedimentation Rate) | hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M25.10) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Weight-Bearing Joint Radiograph [Fistula, unspecified joint M25.10] | Preserved joint-space width (M25.10) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Uric Acid in Fistula, unspecified joint (M25.10: (Gout Target)) | < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M25.10) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Fistula, unspecified joint
Treatment selection for Fistula, unspecified joint depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Fistula, unspecified joint)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on A Phase 3, 56-week, randomised, gold-standard blind, compared against a dummy: What a 513-Participant Study Found 513 patients were randomised. Clinical and experimental rheumatology • 2025-05-15 • Phase III Randomized Trial | N = 513 | 93/100 | PMID 39808286 ↗ |
| New Insights on Darvadstrocel in Patients With Crohn's Disease With Complex Perianal Fistulas:: What a 283-Participant Study Found ADMIRE CD II did not meet its primary endpoint of combined full symptom relief at week 24, with no statistically significant difference between darvadstrocel and placebo. Gastroenterology • 2026-06-15 • Phase III Randomized Trial | N = 283 | 93/100 | PMID 41790076 ↗ |
| New Insights on Benefits and safety of risankizumab for active psoriatic arthritis: 24-week: What a 444-Participant Study Found Treatment with risankizumab resulted in significant improvements versus placebo in key disease outcomes and was well tolerated in patients with PsA who were Bio-IR and/or csDMARD-IR. Annals of the rheumatic diseases • 2022-03-15 • Phase III Randomized Trial | N = 444 | 93/100 | PMID 34815219 ↗ |
| New Insights on Randomized Controlled Trial Comparing Safety, Efficacy, and Cost-effectiveness of: What a 304-Participant Study Found The Biodesign Surgisis anal fistula plug is associated with similar FIQoL and healing rates to surgeon's preference at 12 months. Annals of surgery • 2021-03-01 • Phase III Randomized Trial | N = 304 | 87/100 | PMID 32516229 ↗ |
| Can This Approach Help? Inside the Latest Research on Association Between Biliary Pathogens, Surgical Site Infection, and Pancreatic Previously observed reductions in SSI and CR-POPF in patients that received piperacillin-tazobactam antibiotic prophylaxis are potentially mediated by biliary pathogens that are cefoxitin resistant, specifically Enterobacter spp. Annals of surgery • 2023-09-01 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 37314221 ↗ |
Fistula, unspecified joint Patient Community & “People Like Me” Threads
Filter Fistula, unspecified joint community threads and patient logs by age, biological sex, dosage, and treatment duration.